Safety and Efficacy of Anlotinib in Combination With Irinotecan in Patients With Pretreated Advanced Colorectal Cancer

NCT ID: NCT03545711

Last Updated: 2018-08-06

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 42 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-05-26
• Study Completion Date: 2020-11-24

Brief Summary

Patients with pretreated advanced colorectal cancer are recruited to the phase I portion of this prospective non-randomised study in an escalated dose cohort. The primary endpoint of the dose-escalation phase is to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of anlotinib when given in combination with irinotecan. The phase II (dose-expansion) portion is designed to characterize the safety and potential efficacy of the combination therapy in pretreated advanced colorectal cancer patients.

Conditions

Colo-rectal Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Anlotinib plus Irinotecan

Group Type: EXPERIMENTAL

Anlotinib Hydrochloride with Irinotecan

Intervention Type: DRUG

Dose escalation of anlotinib starts from 8mg qd d1-14/q21d in combination with fixed dose of irinotecan at 180mg/m2 d1/q14d.

Interventions

Anlotinib Hydrochloride with Irinotecan

Dose escalation of anlotinib starts from 8mg qd d1-14/q21d in combination with fixed dose of irinotecan at 180mg/m2 d1/q14d.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• willing and able to provide written informed consent and comply with the requirements of the study
• histologically- or cytologically-confirmed advanced colorectal cancer
• failed or intolerable to at least one prior therapy
• have evidence of measurable disease per RECIST v1.1
• Eastern Collaborative Oncology Group (ECOG) Performance Status ≤ 1
• weight ≥40kg
• life expectancy >12 weeks

Exclusion Criteria

Subjects meeting any of the following criteria are ineligible for participation in the study:

• history of any anti-cancer therapy (including investigational agents) within 28 days prior to study entry
• presence of toxicity of prior anti-cancer therapy that has not resolved to Grade 1, as determined by National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03
• symptomatic brain metastasis requiring active treatment
• any previous malignancy, except for non squamous-cell carcinoma of skin or carcinoma-in-situ of the uterine cervix within 5 years prior to study entry
• active or clinically unstable infection requiring systemic therapy
• unable to swallow oral medications or with gastrointestinal disorders that might interfere with proper absorption of oral drugs
• active digestive ulcer disease, inflammatory bowel disease, intestinal obstruction or any other condition that, in the clinical judgment of the Principal Investigator, may cause severe gastrointestinal bleeding or perforation
• unstable pulmonary embolism, deep vein thrombosis, or other significant arterial/venous thromboembolic event ≤2 months prior to study entry
• history of stroke or transient ischemic attack (TIA) within 12 months prior to study entry
• any of the following abnormal findings in organ or marrow function 1 week prior to study entry:

• Leukocytes < 1.5*10^9/L, or Platelets < 100*10^9/L, or Hb< 90g/L
• Total bilirubin > 1.5 × institutional upper limit of normal (ULN), or AST (aspartate amino transferase)/ALT (alanine amino transferase)> 3 × institutional ULN for liver metastases, > 1.5 × institutional ULN in case of no liver metastases
• any electrolyte imbalance of clinical significance
• creatinine > institutional ULN and creatinine clearance < 60 mL/min
• spot urine protein ≥(2+) or 24-hour proteinuria ≥1.0g/24h
• APTT (activated partial thromboplastin time) or INR (international normalized ratio for prothrombin time) > 1.5 × institutional ULN
• treatment refractory hypertension defined as a blood pressure of systolic> 140 millimeter of mercury (mm Hg) and/or diastolic > 90 mm Hg which cannot be controlled by a single anti-hypertensive agent
• LVEF (left ventricular ejection fraction ) <50%
• history of acute coronary syndromes (including myocardial infarction and unstable angina), coronary artery bypass graft within 6 months prior to study entry, or history or evidence of current ≥ Class II congestive heart failure as defined by New York Heart Association (NYHA)
• present with non-healing fractures of bone or wounds of skin
• pregnant or lactating female
• sexually active female (of childbearing potential) or male unwilling to adopt an effective method of birth control during the course of the study
• serious and/or unstable pre-existing psychiatric disorder
• familial, sociological or geographical conditions that, in the clinical judgment of the Principal Investigator, do not permit compliance with the protocol
• known immediate or delayed hypersensitivity reaction to anlotinib, irinotecan or their excipients
• administration of irinotecan in prior treatments

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Chinese Academy of Medical Sciences

OTHER

Sponsor Role: lead

Responsible Party

Jing Huang

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jing Huang, MD

Role: PRINCIPAL_INVESTIGATOR

Cancer Hospital,CAMS

Locations

Jing Huang

Beijing, , China

Site Status: RECRUITING

Countries

China

Central Contacts

Jing Huang, MD

Role: CONTACT

huangjingwg@163.com

86-10-87788102

Yan Song, M.D

Role: CONTACT

Facility Contacts

Jing Huang, MD

Role: primary

Other Identifiers

NCC201803012

Identifier Type: -

Identifier Source: org_study_id